Aims and scope
Drug and Therapeutics Bulletin (DTB) provides rigorous and independent evaluations of, and practical advice on, individual treatments and the overall management of disease for doctors, pharmacists and other healthcare professionals. The journals aim is to provide informed and unbiased information on medical conditions, medicines and other treatments to enable readers to make informed choices and ensure patients get the best care.
Published monthly by BMJ, DTB conclusions represent a synthesis of the best available medical evidence with opinions from a wide range of specialist and generalist commentators. All contributors are asked to declare whether they have any potential conflicts which are taken into account during the editorial process. All comments must be supported by appropriate evidence.
DTB is wholly independent of the pharmaceutical industry, Government and regulatory authorities and is also free of advertising and other forms of commercial sponsorship.
Over the years, DTB has initiated successful campaigns for the removal or restriction of medicines that it could not recommend, prompted withdrawal of excessive promotional claims and exposed fundamental weaknesses in certain prescribing practice. Surveys of our readership have consistently shown that readers find DTB authoritative, influential and reliable in relation to their decisions, recommendations or advice on treatments. These are just a few of the examples of why DTB is regarded as an indispensable part of evidence-based clinical practice and has been described as both essential reading for practising doctors and as a key information source by the House of Commons Health Select Committee in the UK.
Drug and Therapeutics Bulletin is owned by BMJ.
Index Medicus (Medline), ISI Current Contents (Web of Science), Excerpta Medica (Embase)
ISSN of DTB
For all contact information please refer to the Contact Us page.
Rights and permissions
DTB was a founder member of the International Society of Drug Bulletins (ISDB)
BMJ is a founding member of COPE (the Committee on Publication Ethics), which provides a forum for publishers and Editors of scientific journals to discuss issues relating to the integrity of the work submitted to or published in their journals.
The EQUATOR Network is an international initiative that seeks to improve the value of medical research literature by promoting transparent, accurate reporting of research studies. BMJ is a sponsor of its activities.
BMJ is a founding organisation of the AllTrials initiative, which calls for all past and present clinical trials to be registered and their results reported.